Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $50
Regenxbio Analyst Ratings
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Raises Target Price to $39
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $50
Buy Rating Affirmed for RegenXBio on Strong Clinical Updates and Strategic FDA Engagements
Analysts Are Bullish on Top Healthcare Stocks: Twist Bioscience (TWST), RegenXBio (RGNX)
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), RegenXBio (RGNX) and Laboratory (LH)
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $40
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
RBC Capital Sticks to Their Buy Rating for RegenXBio (RGNX)
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $40
Analysts' Top Healthcare Picks: KalVista Pharmaceuticals (KALV), RegenXBio (RGNX)
RBC Capital Remains a Buy on RegenXBio (RGNX)
Regenxbio Analyst Ratings
Regenxbio Analyst Ratings
Regenxbio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), PepGen Inc. (PEPG) and RegenXBio (RGNX)
Buy Rating Affirmed for RegenXBio Amid Promising Drug Developments and Solid Financials
UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating
RBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)